Breaking News, Financial News

Financial Reports: Icon 2Q11

Costs will grow in advance of Pfizer partnership revenues

ICON 2Q

2Q Revenues: $233 million (+4%)

2Q Earnings: $13 million (-43%)

YTD Revenues: 462 million (+4%)

YTD Earnings: $21 million (-52%)

Comments: ICON’s backlog passed $2.0 billion for the first time As a result of its new long-term partnership with Pfizer, the company anticipates increased 3Q expenses without immediate offsetting revenue gains. Costs will also increase in 4Q, but Pfizer-related revenues are expected to build in that quarter. Direct costs were up 15% in 2Q to $151 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters